Scientists have developed an antigen for malaria vaccine
Share
Researchers from University of Maria Curie-Skłodowska University in Lublin have developed an antigen (a protein substance that causes the production of antibodies in the body), which can be used to make a vaccine against malaria.
Researchers from the Department of Molecular Biology UMCS reserved that
the invention is patent pending and during this procedure they may not
reveal further details. They confirm that their antigen can be used as
the main active ingredient in a vaccine against malaria.
"There
is still a long way from the development of antigen to the vaccine. We
will need a lot of money to fund further research. We will also need to
conduct field studies in areas where malaria is a current problem" -
said the head of the Department of Molecular Biology, UMCS Prof. Nikodem
Grankowski.
Malaria is a tropical parasitic disease caused by
several species of protozoan called Plasmodium. This parasite is highly
adaptive and becomes resistant to medications.
Prof. Grankowski
stressed that previous studies in laboratories have focused on selected
antigens from individual development stages of Plasmodium, which could
result in the development of methods for obtaining human immunity only
in those selected cases.
Antigen developed by researchers from
Lublin can act at any stage of development of malaria parasite and, as
such, used in a vaccine it would offer the chance for full immunity in
humans.
Dr. Marek Tchorzewski from the Department of Molecular
Biology UMCS said that the development of antigen is the result of years
of research on scientific problems related to protein synthesis.
Researchers from Lublin have investigated certain protein synthesis
mechanisms in the cell, mainly the functioning of ribosomes. "They are
nanomachines that synthesize proteins; they are among the most important
molecules in the body" - he explained.
Unwilling to disclose
further details, Tchorzewski said only that these studies have allowed
scientists to understand the function of the ribosome, "understand the
functioning of certain proteins", and identify "molecular events", which
may allow to acquire a permanent immunity to the disease.
"In
the beginning we did not think have a vaccine in mind. We wanted to
solve a scientific problem and we did solved it. In solving this
problem, it turned out that the solution can be used in everyday life,
in the form of a vaccine" - Tchorzewski explained.
He noted that
it today would be impossible to determine when the malaria vaccine would
be ready. "We still have very advanced clinical trials ahead of us, and
these activities are among the most expensive" - noted the researcher.
Antigen
studies of Lublin scientists were supported the Ministry of Science and
Higher Education, which granted PLN 420 thousand to this research
project.
Malaria is one of the deadliest infectious diseases -
next to from AIDS and tuberculosis. Infection occurs after a person is
bitten by a female mosquito of the Anopheles maculipennis species.
According to various estimates, each year 1 to 3 million people die from
malaria worldwide, the vast majority of them being Africans. So far
there is no effective vaccine against this disease. PAP - Science and Scholarship in Poland